Latest News

Researchers have identified a novel subclass of HPV+ head and neck squamous cell carcinoma and demonstrated that treatment could be tailored by tumor type.

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma (HNSCC) and lung cancer.

Aarti Bhatia, MD, MPH, Associate Professor of Medicine (Medical Oncology), has been named Leader of the Head & Neck Disease-Aligned Research Team (DART) for Yale Cancer Center and Smilow Cancer Hospital.

Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.

Comprehensive Viral Genotyping for Head and Neck Cancers.

Researchers developed a new tool aimed at better classifying HPV+ HNSCC patients with good or poor prognosis in an effort to personalize treatment and improve patient outcomes.

Oropharyngeal squamous cell carcinoma (OPSCC) accounts for over half of all head and neck cancers. Since the 1970s, OPSCC has shifted from an environmentally triggered to virally mediated disease due to a sharp rise in human papillomavirus (HPV)-related SCC.

Connecticut Magazine has named 87 Yale Cancer Center and Smilow Cancer Hospital physicians to its 2022 Best Doctors guide.

Head and neck squamous cell carcinoma (HNSCC) is a frequently devastating cancer that affects more than a half million people annually worldwide. In a paper recently published in AACR Journals, Dr. Barbara Burtness reveals the relation of the interaction of TP53 and CDKN2A mutations with elevated tumor mutation burden in HNSCC.